Military Working Dog Whole Blood Product or Substitute - SBIR DHA26BZ01-NV001
Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.
Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.
Funding Amount:
Est. $250,000
Deadline to Apply:
Est. April 29th, 2026.
Objective:
Develop a whole blood product or substitute to aid in hemorrhage control for Military Working Dogs (MWD) after battlefield injury that can be used near the point of injury (POI) and throughout the continuum of care to reduce morbidity and mortality.
Description:
This topic is in support of the DoD Working Dog Strategic Research Plan concerning solutions for bleeding control and coagulopathy support.1 The Military Working Dog (MWD) provides a unique and important service to the warfighter. MWDs serve as sentries, perform tracking and patrol, and are used for the detection of explosives. These activities come with a high risk of injury. Uncontrolled hemorrhage following traumatic injury accounts for over 45% of all MWD battlefield deaths2. The current standard of care for hemorrhage in the MWD is to provide immediate fluid therapy through the delivery of crystalloid fluids as the first-line treatment, which is then followed by a synthetic colloid or hypertonic saline. These treatments also require the administration of supplemental oxygen to maintain appropriate oxygen levels and for the survival of the MWD3. To improve their survival rates, the development of a shelf stable canine whole blood product or substitute is a critical priority
The goal of this topic is to develop a stable canine whole blood product and/or substitute (i.e. hemoglobin or polymer oxygen carriers), intended for canine use at both POI and throughout the continuum of care. The product should have a shelf-life of greater than 3 years and be thermal stable (-9℃ to 60℃) to ensure accessibility in operational environments. The product must primarily replicate the oxygen carrier characteristics of whole blood and demonstrate the ability to be used safely and effectively to treat blood loss following traumatic injury. This research topic does not support the use of canines for testing purposes. Any animal testing would require use of suitable animal models that would approximate the response of a canine.
Blood products derived from canine donors must be negative for canine red blood cell antigens DEA 1.1 and DEA 1.2. Donor animals must also be tested for blood borne diseases including canine brucellosis, hemobartonellosis, Borrelia burgdorferi (Lyme disease), Dirofilaria immitis (heartworm disease), Ehrlichia canis, Rocky Mountain spotted fever, Coccidioides immitis, Babesia canis, Babesia gibsoni, Mycoplasma haemocanis and plasma levels of von Willebrand factor. All donor animals must be current on immunizations for canine distemper, hepatitis, parainfluenza, leptospirosis, parvovirus, Bordatella, coronavirus and rabies virus as applicable.
Who will win?
If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.
Who is eligible to apply?
Any company that meets the following criteria:
For-profit company
U.S.-owned and controlled.
500 or fewer employees (including affiliates)
How Can BW&CO Help?
1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.
2) Proposal strategy and review.
3) Administrative & compliance support.
Request to talk with a member of our team by completing the form below: